You have no items in your shopping cart.

Cart empty

Shop By

Listed in Category: Nervous system

Actovegin 2 ml 25 vials

Availability: In Stock



Active ingredients: deproteinized calves blood gemoderivat
Manufacturer: TAKEDA Pharmaceuticals
Country of origin: Austria
General description: The drug that activates metabolism in tissues, improves trophism and stimulates the regeneration process
Product form: 25 vials of 2 ml

Dosage form
Solution for injection transparent, yellowish, practically free from particles.
deproteinized gemoderivat from the blood of calves 40 mg

Auxiliary substances: sodium chloride, water d/I.
Pharmacological action
A drug that activates metabolism in tissues, reduces tissue hypoxia, improves trophic and stimulating the regeneration process. Represents gemoderivat which is prepared by dialysis and ultrafiltration (permeate compounds with a molecular weight less than 5000 daltons).

Positively affects the transport and utilization of glucose stimulates oxygen consumption (which leads to stabilization of plasma membranes of cells during ischemia and reduced the formation of lactate) having thus anti-hypoxic action.

Actovegin® increases the concentration of ATP, ADP, phosphocreatine, and amino acids (glutamate, aspartate) and GABA.

Actovegin effect begins to appear no later than after 30 min (10-30 min) after parenteral administration and reaches a maximum, on average, after 3 hours (2-6 hours).
Using methods impossible pharmacokinetic study the pharmacokinetic characteristics (absorption, distribution, excretion) of the active components of Actovegin®, because it consists only of physiological components which are normally present in the body.

So far not discovered reduction in pharmacological effectiveness hemoderivative in patients with altered pharmacokinetics (including with hepatic or renal failure, metabolic changes associated with advanced age, peculiarities of metabolism in newborns).
Side effects
Allergic reactions: skin rash, hyperemia skin, hyperthermia, up to anaphylactic shock.

Special conditions
In connection with the potential of anaphylactic reactions are recommended to carry out a test (a test injection of 2 ml I/m) prior to infusion.

In the case of the V/m method of application the drug should be administered slowly at not more than 5 ml.

Solutions Actovegin have a slightly yellowish tint. The color intensity may vary from one batch to another depending on the features used original materials, but this does not affect the efficacy and tolerability of the drug.

You should not use an opaque solution or a solution containing particles.

After opening the ampoule or vial, the solution can not be stored.
— metabolic and vascular disorders of the brain (i.e. ischemic stroke, craniocerebral injury);

— peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers);

— wound healing (ulcers of various etiologies, trophic disorders /pressure ulcers, burns, impaired wound healing processes);

— prevention and treatment of radiation injuries of skin and mucous membranes during radiation therapy.
— decompensated heart failure;

pulmonary edema,

— oliguria;

— anuria;

— fluid retention in the body;

— hypersensitivity to the drug component;

— hypersensitivity to similar drugs.

With caution should designate product if hyperchloremia, hypernatremia.
Drug interactions
Drug interactions drug Actovegin® is not installed.

However, to avoid possible pharmaceutical incompatibility, do not add other medications to infusion solution of Actovegin.

To Top
© 2016-2022
All right reserved.